Target intelligence / Profile preview

Canine parainfluenza virus antigen (CPIV-Ag)

Target
CPIV-Ag
Molecular classification
Viral protein, Glycoprotein, Other
01

Overview

Canine parainfluenza virus antigen refers to the immunogenic proteins of the canine parainfluenza virus (CPIV), also known as parainfluenza virus 5 (PIV5) or Orthorubulavirus mammalis. CPIV is a highly contagious, enveloped, single-stranded RNA virus belonging to the Paramyxoviridae family. It is a primary viral pathogen responsible for canine infectious respiratory disease complex (CIRDC), commonly known as kennel cough. The key antigenic targets on the virus include the hemagglutinin-neuraminidase (HN) glycoprotein, which mediates viral attachment to host epithelial cells, and the fusion (F) protein, which facilitates viral entry into the host cell.

Vaccines containing attenuated or inactivated CPIV antigens are widely used in veterinary medicine to stimulate active immunity, inducing the production of neutralizing antibodies and cell-mediated immune responses. While these vaccines do not provide sterilizing immunity, they significantly reduce the severity of clinical symptoms, viral replication, and shedding in infected dogs. In addition to vaccines, CPIV antigens are the primary targets for diagnostic assays, such as lateral flow rapid tests and ELISAs, which are used to detect active infections in veterinary clinics.

Other names
Canine parainfluenza virus antigenCPIV antigenParainfluenza virus 5 antigenPIV5 antigenOrthorubulavirus mammalis antigenSimian virus 5 antigenSV5 antigen
02

Mechanism of action

Active immunization to stimulate the host immune system to produce neutralizing antibodies and cell-mediated immune responses against canine parainfluenza virus, thereby preventing or reducing viral replication, shedding, and clinical severity of canine infectious respiratory disease complex.

03

Biological functions

Viral attachmentViral entryImmune responseOther
04

Disease associations

InfectionOther
05

Safety considerations

Post-vaccinal adverse events (e.g., lethargy, fever, injection site soreness, sneezing, nasal discharge)Risk of reversion to virulence in modified-live vaccinesIncomplete protection (lack of sterilizing immunity)Hypersensitivity reactions or anaphylaxis
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Neutralizing antibody titerSerum IgG antibody levelsMucosal IgA antibody levelsViral sheddingCPIV antigen detection

Beyond the preview

Go deeper on Canine parainfluenza virus antigen (CPIV-Ag).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canine parainfluenza virus antigen (CPIV-Ag).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call